Latest Breaking News On - Prnewswire boehringer ingelheim - Page 2 : comparemela.com

Boehringer Ingelheim introduces NexGard SPECTRA® for dogs in India

(This story has not been edited by THE WEEK and is auto-generated from a PTI

Kallahalli umeshVinod gopalJasjeet josanPrnewswire boehringer ingelheimMakrand chavanCentral drugs standard control organisationNational veterinary foundationFederation of small animal practitioners associationsBoehringer ingelheimAnimal healthAssociation for veterinary dermatologyCountry headGeneral secretarySmall animal practitioners associationsVeterinary dermatologyHuman pharma

Boehringer Ingelheim Named Official Animal Health Company Partner of the Atlanta Braves

/PRNewswire/ Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the.

United statesPrnewswire boehringer ingelheimJim allenRandolph leggAnimal healthAnimal health companyBoehringer ingelheim animal health united statesAtlanta braves foundationBoehringer ingelheim animal healthBoehringer ingelheimAtlanta bravesOfficial animal health companyIngelheim animal healthAtlanta braves senior vice presidentBattery atlantaHuman pharma

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Prnewswire boehringer ingelheimLamine mbowEngagers tcesStefanj schererParker institute for cancer immunotherapyBoehringer ingelheimAnimal healthT cell engagersT cell receptor antigenCross reactivity engineGlobal headCancer immunologyImmune modulationHuman pharmaSan franciscoWestlake village biopartners

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor,.

United statesPrnewswire boehringer ingelheimColl cardiolJ nephrol renovascKatherine tuttleCarinne brouillonBoehringer ingelheim pharmaceuticals incKidney research instituteNephrology divisionAnimal healthAmerican society of nephrologyBoehringer ingelheimOxford population healthUniversity of washingtonOxford populationAmerican society

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKatherine tuttleColl cardiolCarinne brouillonJ nephrol renovascNlet alPrnewswire boehringer ingelheimAnimal healthKidney research instituteUniversity of washingtonOxford population healthNephrology divisionBoehringer ingelheimBoehringer ingelheim pharmaceuticals incAmerican society of nephrologyOxford population